Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview

Liu ET. Expression genomics and drug development: towards predictive pharmacology. Brief Funct Genomic Proteomic 2005 Feb;3(4):303–21.CrossRefGoogle Scholar

Lindsey MA. Target discovery. Nat Rev Drug Discov 2003 Oct;2(10):831–8.CrossRefGoogle Scholar

Chanda SK and Caldwell JS. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov Today 2003 Feb 15;8(4):168–74.CrossRefGoogle Scholar

Alaiya A, Al-Mohanna, and Linder S. Clinical cancer proteomics: promises and pitfalls. J Proteome Res 2005 Jul–Aug;4(4):1213–22.CrossRefGoogle Scholar

Walgren JL and Thompson DC. Application of proteomic technologies in the drug development process. Toxicol Lett 2004 Apr 1;149(1–3):377–85.CrossRefGoogle Scholar

Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH, and Levine MN, for the National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006 May 18;354(20):2103–11.CrossRefGoogle Scholar

Feng Z, Prentice R, and Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004 Sep;5(6):709–19.CrossRefGoogle Scholar

Mehta T, Tanik M, and Allison DB. Towards sound epistemological foundations of statistical methods for high-dimensional biology. Nat Genet 2004 Sep;36(9):943–7.CrossRefGoogle Scholar

Hayes DF, Bast RC, Desch CE, Fritche H, Jr, Kemeny NE, Jessup M, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, and Winn RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996 Oct 16;88(20):1456–66.CrossRefGoogle Scholar

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005 Aug 17;97(16):1180–4.Google Scholar

Schrorohl AS, Holten-Andersen M, Sweep F, Schmitt M, Harbeck N, Foekens J, and Brunner N, on behalf of the European Organization for Research and Treatment of Cancer (EORTC) Receptor and Biomarker Group. Tumor markers: from laboratory to clinical utility. Mol Cell Proteomics 2003 Jun;2(6):378–87.Google Scholar

Deyo RA and Jarvik JJ. New diagnostic tests: breakthrough approaches or expensive add-ons? Ann Intern Med 2003 Dec 2;139(11):950–1.Google Scholar

Bossuyt PM, Reitsma JB, Bruns DE, et al, for the STARD group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Clin Chem 2003;49:1–6.PubMedCrossRefGoogle Scholar

Schmitt M, Harbeck N, Daidone MG, Brunner N, Duffy MJ, Foekens JA, and Sweep FC. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int J Oncol 2004 Nov;25(5):1397–406.Google Scholar

Dervieux T, Meshkin B, and Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 2005 Jun 3;573(1–2):180–94.Google Scholar

Lindpaintner K. Pharmacogenetics and the future of medical practice. Br J Clin Pharmacol 2002 Aug;54(2):221–30.CrossRefGoogle Scholar

Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today 2005 Jan 15;10(2):139–47.CrossRefGoogle Scholar

Vogelstein B and Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004 Aug;10(8):789–99.CrossRefGoogle Scholar

Segal E, Friedman N, Koller D, and Regev A. A module map showing conditional activity of expression modules in cancer. Nat Genet 2004 Oct;36(10):1090–8. Epub 2004 Sep 26.CrossRefGoogle Scholar

Hackett JL and Gutmann S. Introduction to the Food and Drug Administration (FDA) regulatory process. J Proteome Res 2005 Jul–Aug;4(4):1110–3.CrossRefGoogle Scholar

Bast RC, Jr, Lilja H, Urban N, Rimm DL, Fritche H, Grey J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, and Hruszkewycz A. Translational crossroads for biomarkers. Clin Cancer Res 2005 Sep 1;11(17):6103–8.Google Scholar

Gutman S. Regulatory issues in tumor marker development. Semin Oncol 2002 Jun;29(3):294–300.CrossRefGoogle Scholar

Katz R. FDA: evidentiary standards for drug development and approval. NeuroRx 2004 Jul;1(3):307–16.CrossRefGoogle Scholar

Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004 Apr;1(2):189–95.CrossRefGoogle Scholar

Harper CC, Phillip R, Robinowitz M, and Gutman SI. FDA perspectives on pharmacogenetic testing. Expert Rev Mol Diagn 2005 Sep;5(5):643–8.Google Scholar

Hirschfeld S and Pazdur R. Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 2002 May;42(2):137–43.CrossRefGoogle Scholar

Hammond ME and Taube SE. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin Oncol 2002 Jun;29(3):213–21.CrossRefGoogle Scholar

Rebbeck TR. Inherited genetic markers and cancer outcomes: personalized medicine in the postgenomic era. J Clin Oncol 2006, May1; 24(13):1972–4.CrossRefGoogle Scholar

Piccart-Gebhart MJ. Anthracyclines and the tailoring of treatment for early breast cancer. N Engl J Med 2006 May 18;354(20):2177–9.CrossRefGoogle Scholar

Walker JV and Nitiss JL. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 2002;20(4):570–89.PubMedCrossRefGoogle Scholar

Nitiss JL and Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996 Jun;32A(6):958–66.CrossRefGoogle Scholar

Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, and Ejlertsen B. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005 Oct 20;23(30):7483–90.CrossRefGoogle Scholar

Mueller R, Parkes RK, Andrulis I, and O’Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004 Apr;39(4):288–97.CrossRefGoogle Scholar

Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, and Vikhanskaya F. p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic Acids Res 1996 Nov 15;24(22):4464–70.CrossRefGoogle Scholar

Brandt TL, Fraser DJ, Leal S, Halandras PM, Kroll AR, and Kroll DJ. c-Myb trans-activates the human DNA topoisomerase IIalpha gene promoter. J Biol Chem 1997 Mar 7;272(10):6278–84.CrossRefGoogle Scholar

Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, and Hortobagyi GN. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004 Apr;3(4):379–98.CrossRefGoogle Scholar

Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, and Piccart MJ. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002 May;8(5):1107–16.Google Scholar

Jarvinen TA and Liu E. HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 2003 Apr;78(3):299–311.CrossRefGoogle Scholar

Willis S, Hutchins AM, Hammet F, Ciciulla J, Soo WK, White D, van der Spek P, Henderson MA, Gish K, Venter DJ, and Armes JE. Detailed gene copy number and RNA expression analysis of the 17q12–23 region in primary breast cancers. Genes Chromosomes Cancer 2003 Apr;36(4):382–92.CrossRefGoogle Scholar

Chaurand P, Sanders ME, Jensen RA, and Caprioli RM. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 2004 Oct;165(4):1057–68.Google Scholar

Lindsey MA. Finding new drug targets in the 21st century. Drug Discov Today 2005 Dec;10(23–24):1683–7.CrossRefGoogle Scholar

Strohman R. Maneuvering in the complex path from genotype to phenotype. Science 2002 Apr 26;296(5568):701–3.CrossRefGoogle Scholar

Coggon D, Martyn C, Palmer KT, and Evanoff B. Assessing case definitions in the absence of a diagnostic gold standard. Int J Epidemiol 2005 Aug;34(4): 949–52.CrossRefGoogle Scholar

Colburn WA and Lee JW. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 2003;42(12):997–1022.PubMedCrossRefGoogle Scholar

Colburn WA. Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 2003 Apr;43(4):329–41.CrossRefGoogle Scholar

Frank R and Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003 Jul;2(7):566–80.CrossRefGoogle Scholar

Fishman MC and Porter JA. Pharmaceuticals: a new grammar for drug discovery. Nature 2005 Sep 22;437(7058):491–3.CrossRefGoogle Scholar

Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999 Jan;156(1):5–10.Google Scholar

Semmes OJ, Feng Z, Adam BL Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welch MJ, White N, Winget M, Yasui Y, Zhang Z, and Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005 Jan;51(1):102–12.Google Scholar

Kapp EA, Schutz F, Connolly LM, Chakel JA, Meza JE, Miller CA, Fenyo D, Eng JK, Adkins JN, Omenn GS, and Simpson RJ. An evaluation, comparison, and accurate benchmarking of several publicly available MS/MS search algorithms: sensitivity and specificity analysis. Proteomics 2005 Aug;5(13):3475–90.Google Scholar

Omenn GS. Advancement of biomarker discovery and validation through the HUPO plasma proteome project. Dis Markers 2004;20(3):131–4.PubMedGoogle Scholar

White CN, Chan DW, and Zhang Z. Bioinformatics strategies for proteomic profiling. Clin Biochem 2004 Jul;37(7):636–41.CrossRefGoogle Scholar

Villanueva J, Phillip J, Chaparro CA, Li Y, Toledo-Crow R, deNoyer L, Fleisher M, Robbins R, and Tempst P. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 2005 Jul–Aug;4(4):1060–72.CrossRefGoogle Scholar

Shin H and Markey MK. A machine learning perspective on the development of clinical decision support systems utilizing mass spectra of blood samples. J Biomed Inform 2006 Apr;39(2):227–48.CrossRefGoogle Scholar

Listgarten J and Emili A. Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2005 Apr;4(4):419–34.CrossRefGoogle Scholar

Lindon JC, Nicholson JK, Holmes E, et al, for The Standard Metabolic Reporting Structure Working Group. Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol 2005 Jul;23(7):833–8.CrossRefGoogle Scholar

Zhang Z and Chan DW. Cancer proteomics: in pursuit of “true” biomarker discovery. Cancer Epidemiol Biomarkers Prev 2005 Oct;14(10):2283–6.CrossRefGoogle Scholar

Simon R. Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 2005 Jun 15;97(12):866–7.CrossRefGoogle Scholar

Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005 Oct 10;23(29):7332–41.CrossRefGoogle Scholar

Allison DB, Cui X, Page GP, and Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006 Jan;7(1):55–65.CrossRefGoogle Scholar

Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL, Jr, Qu Y, Potter JD, Winget M, Thornquist M, and Feng Z. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 2003 Jul;4(3):449–63.CrossRefGoogle Scholar

Tao WA and Asbersold R. Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Curr Opin Biotechnol 2003 Feb;14(1):110–8.CrossRefGoogle Scholar

Schlosser G, Pocsfalvi G, Huszar E, Malorni, and Hudecz F. MALDI-TOF mass spectrometry of a combinatorial peptide library: effect of matrix composition on signal suppression. J Mass Spectrom 2005 Dec;40(12):1590–4.CrossRefGoogle Scholar

Sun W, Wu S, Wang X, Zheng D, and Gao Y. An analysis of protein abundance suppression in data dependent liquid chromatography and tandem mass spectrometry with tryptic peptide mixtures of five known proteins. Eur J Mass Spectrom (Chichester, Eng) 2005;11(6):575–80.CrossRefGoogle Scholar

Wang W, Zhou H, Lin H, Roy S, Shaler TA, Hill LR, Norton S, Kumar P, Anderle M, and Becker CH. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal Chem 2003 Sep 15;75(18):4818–26.CrossRefGoogle Scholar

Feng Z and Yasui Y. Statistical considerations in combining biomarkers for disease classification. Dis Markers 2004;20(2):45–51.PubMedGoogle Scholar

Zolg JW and Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol Cell Proteomics 2004 Apr;3(4):345–54.CrossRefGoogle Scholar

Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, and Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001 Jul 18;93(14):1054–61.CrossRefGoogle Scholar

Sledge GW, Jr. What is targeted therapy? J Clin Oncol 2005 Mar 10;23(8): 1614–5.CrossRefGoogle Scholar

Paik S. Clinical trial methods to discover and validate predictive markers for treatment response in cancer. Biotechnol Annu Rev 2003;9:259–67.PubMedGoogle Scholar

McShane LM, Altman DG, and Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 2005 Jul 20;97(14):1023–5.Google Scholar

Conley BA and Taube SE. Prognostic and predictive markers in cancer. Dis Markers 2004;20(2):35–43.Google Scholar

Jansen AC, van Aalst-Cohen ES, Hutten BA, Buller HR, Kastelein JJ, and Prins MH. Guidelines were developed for data collection from medical records for use in retrospective analyses. J Clin Epidemiol 2005 Mar;58(3):269–74.CrossRefGoogle Scholar

Colantonio DA and Chan DW. The clinical application of proteomics. Clin Chim Acta 2005 Jul 24;357(2):151–8.CrossRefGoogle Scholar

Hu J, Coombes KR, Morris JS, and Baggerly KA. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 2005 Feb;3(4):322–31.CrossRefGoogle Scholar

Sargent DJ, Conley BA, Allegra C, and Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005 Mar 20;23(9):2020–7.CrossRefGoogle Scholar

American Society of clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996 Feb;14(2):671–9.Google Scholar

Hirschfeld S and Pazdur R. Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 2002 May;42(2):137–43.CrossRefGoogle Scholar

Colburn WA. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J Clin Pharmacol 2000 Dec;40(12 Pt 2):1419–27.Google Scholar

Floyd E and McShane TM. Development and use of biomarkers in oncology drug development. Toxicol Pathol 2004 Mar–Apr;32 Suppl 1:106–15.CrossRefGoogle Scholar

Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989 Apr;8(4):431–40.CrossRefGoogle Scholar

Fleming TR and DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996 Oct 1;125(7):605–13.Google Scholar

Buyse M and Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998 Sep;54(3):1014–29.CrossRefGoogle Scholar

Buyse M, Molenberghs G, Burzykowski T, Renard D, and Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000 Mar;1(1):49–67.CrossRefGoogle Scholar

Burzykowski T, Molenberghs G, Buyse M, Geys H, and Renard D. Validation of surrogate endpoints in multiple randomized clinical trials with failure time end points. Appl Stat 2001 50:405–22.Google Scholar

DeGruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Firedman L, Gail M, Prentice R, Wittes J, and Zeger S. Consideration in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health Workshop. Control Clin Trials 2001, 22:485–502.CrossRefGoogle Scholar

Xu J, Zeger SL. Joint analysis of longitudinal data comprising repeated measures and times to events. Appl Stat 2001 50:375–387.Google Scholar

Mayer D. Essential Evidence-Based Medicine. Cambridge University Press, UK, USA, Australia, Spain, South America; Bk&CD-Rom edition (June 17, 2004).Google Scholar

Fletcher RH and Fletcher SW. Clinical Epidemiology: The Essentials. Lippincott Williams & Wilkins, Philadelphia, Baltimore, New York, London, Buenos Aires Hong Kong, Sidney, Tokyo; 4th edition (March 2005)Google Scholar

Lesko LJ and Atkinson AJ, Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001;41:347–66.PubMedCrossRefGoogle Scholar

Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, and Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999 Aug 4;91(15):1281–7.CrossRefGoogle Scholar

Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002 Apr;8(4):935–8.Google Scholar

Williams G, Pazdur R, and Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. J Biopharm Stat 2004 Feb;14(1): 5–21.CrossRefGoogle Scholar

Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002;7(5):401–9.PubMedCrossRefGoogle Scholar

Johnson JR, Williams G, and Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003 Apr 1;21(7):1404–11.CrossRefGoogle Scholar

Meyerson LJ, Wiens B, LaVange LM, and Koutsoukos AD. Quality control of oncology clinical trials. Hematol Oncol Clin North Am 2000 Aug;14(4):953–71, x.CrossRefGoogle Scholar

Cooper R and Kaanders JH. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls. Eur J Cancer 2005 Jun;41(9):1261–6.CrossRefGoogle Scholar

Kelloff GJ and Sigman CC. New science-based endpoints to accelerate oncology drug development. Eur J Cancer 2005 Mar;41(4):491–501.CrossRefGoogle Scholar

Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, and Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001 Jan 1;19(1):265–72.Google Scholar

Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, and Slamon DJ. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 2004 Jun 1;10(11):3885–96.CrossRefGoogle Scholar

Sargent D and Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002 Jun;29(3):222–30.CrossRefGoogle Scholar

Pajak TF, Clark GM, Sargent DJ, McShane LM, and Hammond ME. Statistical issues in tumor marker studies. Arch Pathol Lab Med 2000 Jul;124(7):1011–5.Google Scholar

Lagakos SW. The challenge of subgroup analyses-Reporting without distorting. N Engl J Med 2006 April 20, 354(16):1667–9.CrossRefGoogle Scholar

Westfall PH and Young SS. Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. Wiley Series in Probability and Statistics, New York, Canada (1993).Google Scholar

Ramnarayan P, Kapoor RR, Coren M, Nanduri V, Tomlinson AL, Taylor PM, Waytt JC, and Brotto JF. Measuring the impact of diagnostic decision support on the quality of clinical decision making: development of a reliable and valid composite score. J Am Med Inform Assoc 2003 Nov–Dec;10(6):563–72.CrossRefGoogle Scholar

Hwang D, Rust AG, Ramsey S, Smith JJ, Leslie DM, Weston AD, de Atauri P, Aitchison JD, Hood L, Siegel AF, and Bolouri H. A data integration methodology for systems biology. Proc Natl Acad Sci USA 2005 Nov 29;102(48):17296–301.CrossRefGoogle Scholar

Simon RM, Korn EL, McShane LM, Radmacher MD, Wright GW, and Zhao Y. Design and Analysis of DNA Microarray Investigations. Springer, New York (2003).Google Scholar